FDA accepts NDA for Vimovo for treatment of arthritis and ankylosing spondylitis

Pozen announced that a New Drug Application (NDA) for Vimovo (formerly PN 400), a fixed-dose combination tablet containing enteric-coated naproxen and immediate-release esomeprazole, has been filed and accepted for review by the FDA for the treatment of the signs and symptoms of osteoarthritis (OA), rheumatoid arthritis (RA), and ankylosing spondylitis (AS) in patients who are at risk of developing non-steroidal anti-inflammatory drug (NSAID) associated gastric ulcers.

Vimovo is a combination agent containing a pain relieving NSAID and a proton pump inhibitor (PPI).

For more information call (919) 913-1030 or visit www.pozen.com.